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Abstract
Background: The MenAfriNet Consortium supports strategic implementation of case-based 
meningitis surveillance in key high-risk countries of the African meningitis belt: Burkina Faso, 
Chad, Mali, Niger, and Togo. We describe bacterial meningitis epidemiology in these 5 countries 
in 2015–2017.
Methods: Case-based meningitis surveillance collects case-level demographic and clinical 
information and cerebrospinal fluid (CSF) laboratory results. Neisseria meningitidis (Nm), 
Streptococcus pneumoniae (Sp), or Haemophilus influenzae (Hi) cases were confirmed and Nm/Hi 
were serogrouped/serotyped by real-time PCR, culture, or latex agglutination. We calculated 
annual incidence in participating districts in each country in cases/100,000 population.
Results: From 2015–2017, 18,262 suspected meningitis cases were reported; 92% had a CSF 
specimen available, of which 26% were confirmed as Nm (n=2,433; 56%), Sp (n=1,758; 40%), or 
Hi (n=180; 4%). Average annual incidences for Nm, Sp, and Hi, respectively, were 7.5, 2.5, and 
0.3. Nm incidence was 1.5 in Burkina Faso, 2.7 in Chad, 0.4 in Mali, 14.7 in Niger, and 12.5 in 
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Togo. Several outbreaks occurred: NmC in Niger in 2015–2017, NmC in Mali in 2016, and NmW 
in Togo in 2016–2017. Of Nm cases, 53% were NmC, 30% NmW, and 13% NmX. Five NmA 
cases were reported (Burkina Faso, 2015). NmX increased from 0.6% of Nm cases in 2015 to 27% 
in 2017.
Conclusions: Though bacterial meningitis epidemiology varied widely by country, NmC and 
NmW caused several outbreaks, NmX increased though was not associated with outbreaks, and 
overall NmA incidence remained low. An effective low-cost multivalent meningococcal conjugate 
vaccine could help further control meningococcal meningitis in the region.
Introduction
For over 100 years, the meningitis belt of sub-Saharan Africa—stretching from Senegal to 
Ethiopia and including over 400 million people in 26 countries—experienced high endemic 
rates of meningitis, annual seasonal outbreaks, and explosive epidemics occurring every 5–
10 years [1]. Prior to the introduction of the meningococcal serogroup A conjugate vaccine 
(MACV, MenAfriVac®) in 2010, approximately 90% of all meningitis cases during 
epidemics in the region were attributable to Neisseria meningitidis serogroup A (NmA) [2]. 
From 2010–2018, MACV was progressively rolled out using mass vaccination campaigns in 
22 of the 26 meningitis belt countries [3]. As a result, a dramatic reduction (≥99%) in both 
NmA disease and asymptomatic nasopharyngeal carriage was observed [4, 5]. To sustain 
this reduction and protect more recent birth cohorts, beginning in 2016, MACV has been 
introduced into the routine childhood immunization programs in 8 countries to date, 
accompanied by catch-up campaigns for older children [3].
MenAfriNet is an international consortium led and implemented by African Ministries of 
Health, Agence de Médecine Préventive, the U.S. Centers for Disease Control and 
Prevention (CDC), and the World Health Organization (WHO), with support and 
collaboration from other international and non-governmental organizations [6]. MenAfriNet 
was established in 2014 to support strategic implementation of case-based meningitis 
surveillance in 5 key high-risk countries of the African meningitis belt: Burkina Faso, Chad, 
Mali, Niger, and Togo. The primary aims of MenAfriNet were to (1) develop a high-quality, 
sustainable, case-based meningitis surveillance network using standardized tools, (2) assess 
changes in meningitis epidemiology and vaccine impact, and (3) inform vaccine policy 
decisions and new vaccine development.
By 2015 all 5 MenAfriNet countries had completed MACV mass vaccination campaigns 
targeting persons aged 1–29 years, and all but Togo introduced MACV into the routine 
immunization program for children aged 9–18 months (Supplemental Table 1) [3]. In 
addition, all 5 countries introduced Haemophilus influenzae serotype b (Hib) conjugate 
vaccine into the routine immunization program during 2005–2008, and 4 out of 5 countries 
introduced pneumococcal conjugate vaccine (PCV) for infants in 2011–2014.
In this context, we aimed to describe the epidemiology of bacterial meningitis in the 5 key 
high-risk MenAfriNet countries using the first 3 years (2015–2017) of data collected via 
strengthened case-based meningitis surveillance.
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Methods
MenAfriNet countries
Burkina Faso, Niger, and Togo began MenAfriNet-supported data collection in January 
2015; Mali began in May 2015 and Chad began in April 2016. All districts in Burkina Faso 
and selected districts in the other 4 countries were included in MenAfriNet [6]. By 2017, 
115 (33%) of 347 districts in these countries were included in MenAfriNet and ~32.7 
million people were under case-based meningitis surveillance.
Case-based meningitis surveillance
In each of the 5 countries, case-level demographic and clinical information, as well as 
cerebrospinal fluid (CSF) specimens, were collected from all suspected meningitis cases in 
MenAfriNet districts using WHO and MenAfriNet guidelines and surveillance tools [7–9]. 
A paper case notification form was completed at the health facility for each suspected case, 
and district surveillance officers entered the data into a surveillance database. If a CSF 
specimen was collected, a copy of the case notification form accompanied the specimen 
sequentially to district, regional, and national reference laboratories; though in some 
settings, some intermediate laboratory levels were skipped. At each level, laboratory results 
were entered into a laboratory database. The surveillance office merged the surveillance 
database with the laboratory database to generate a master database, which included cases 
with and without CSF specimens and laboratory results. This master database was sent to the 
data management team at WHO-AFRO, and the databases from each country were merged 
into a central MenAfriNet database by the MenAfriNet data management team. Each 
country that participated in the MenAfriNet Consortium made substantial efforts to maintain 
high-quality cased-based surveillance and aimed to have a CSF specimen collected and 
tested for ≥80% of suspected cases. Key performance indicators and data completeness and 
quality are described elsewhere [10].
Case definitions
According to WHO case definitions for enhanced meningitis surveillance in the meningitis 
belt [11], a suspected meningitis case was defined as a sudden onset of fever ≥38.5°C with 
neck stiffness, altered consciousness, or other meningeal signs (including flaccid neck, 
bulging fontanel, or convulsions in young children). Probable bacterial meningitis was a 
suspected case with turbid, cloudy, purulent, or xanthochromic CSF; presence of gram-
negative diplococci, gram-positive diplococci, or gram-negative bacilli on microscopic 
examination of CSF; or a CSF white cell count >10/mm3. A confirmed case of meningitis 
was a suspected or probable case with N. meningitidis (Nm), Streptococcus pneumoniae 
(Sp), or H. influenzae (Hi) isolated from CSF by culture or detected in CSF by real-time 
polymerase chain reaction (rt-PCR) or latex agglutination [12]. Cases did not have to meet 
the probable case definition in order to be confirmed.
Laboratory methods
CSF specimens were transported from local healthcare facilities to district laboratories, 
which conducted preliminary lab testing such as cytology, Gram staining, or latex 
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agglutination, depending on laboratory capacity. CSF specimens were then sent to a national 
reference laboratory in both trans-isolate medium at room temperature for culture and a 
cryotube via a cold chain for rt-PCR targeting the sodC gene for Nm, lytA for Sp, and hpd 
for Hi [13, 14]. All national reference laboratories in MenAfriNet countries were trained on 
rt-PCR using standard assays [15]. In Chad, all laboratory testing was done at the national 
level. In the case of discrepant results for case confirmation, methods were considered 
confirmatory in the following order: rt-PCR, culture, latex agglutination. Six meningococcal 
serogroups (A, B, C, W, X, or Y) and Hi serotypes (b or non-b) were determined using latex 
agglutination or rt-PCR, with rt-PCR considered definitive in cases of discrepancy [14]. Any 
meningococcal specimens that were not identified as one of the six assessed serogroups by 
rt-PCR or latex agglutination were considered indeterminate (NmInd), a category which 
includes both non-ABCWXY serogroups and nongroupable (unencapsulated) strains. 
Pneumococcal serotyping data from Burkina Faso are presented elsewhere [16].
Statistical methods
We analyzed data from meningitis cases reported in MenAfriNet districts from January 1, 
2015 to December 31, 2017. For the purposes of this analysis, a district was included as a 
MenAfriNet district starting January 1 of the first full calendar year of surveillance 
implementation; districts that implemented case-based surveillance mid-year were not 
included until the beginning of the next calendar year. Annual incidences (cases per 100,000 
persons) were calculated for MenAfriNet-participating districts in each country using 
projected age-stratified population census estimates provided by each country. For suspected 
and probable cases, crude incidences were calculated. For laboratory-confirmed cases, 
annual incidence was adjusted for the age-stratified proportion of cases with a CSF 
specimen tested at a national laboratory, where culture and rt-PCR were performed. Within 
each age stratum (<1 year, 1–4 years, 5–9 years, 10–14 years, 15–29 years and ≥30 years), 
the number of cases confirmed by culture or rt-PCR at a national laboratory for a specific 
pathogen was divided by the number of cases with CSF tested via culture or rt-PCR at a 
national laboratory. This confirmation proportion was then applied to the number of 
suspected meningitis cases within that age stratum for which no diagnostic testing was 
performed; this number was then added to confirmed cases to calculate the adjusted 
incidence. For MenAfriNet-wide incidences, adjusted annual incidences from participating 
districts in each country for each year of their participation in MenAfriNet were averaged. 
CFRs were calculated by dividing the number of reported deaths by the total number of 
cases with a reported outcome.
Data were analyzed using SAS v9.4. Analysis of data collected through routine MenAfriNet 
surveillance was determined by the CDC’s Human Research Protection Office to be public 
health non-research, and Institutional Review Board review was not required by any 
participating institution.
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Results
Suspected and probable meningitis cases
From 2015–2017, 18,262 suspected meningitis cases were reported in MenAfriNet districts: 
8,362 in Burkina Faso, 166 in Chad (2017 only), 495 in Mali (2016–2017 only), 8,413 in 
Niger, and 826 in Togo (Fig 1, Table 1); of 12,920 (71%) with a reported outcome, 1,095 
(8%) were fatal. The majority of suspected meningitis cases (92%) had a CSF specimen 
available for analysis. Seventy-nine percent of specimens were tested at either district, 
regional, or national reference laboratories by at least one confirmatory test: 15% by latex, 
19% by culture, and 73% by rt-PCR.
An eighth (13%, n=2,364) of suspected meningitis cases detected by this case-based 
surveillance system occurred among children aged <1 year and 39% (n=7,062) occurred in 
children aged <5 years (Table 1). Thirty-seven percent (n=6,190) of all suspected cases met 
the probable case definition. The annual average incidences of suspected and probable 
meningitis were 31.3 and 11.2 cases per 100,000, respectively (Table 3).
Laboratory-confirmed meningitis
A quarter (n=4,371, 26%) of suspected cases that had a CSF specimen obtained were 
laboratory-confirmed via latex, culture, or rt-PCR as either Nm (56%; n=2,433), Sp (40%; 
n=1,758), or Hi (4%; n=180) (Table 2). The CFR for Sp was 17%, compared to 6% for Nm 
and 9% for Hi. Median age was 9 years among persons with Nm meningitis (interquartile 
range [IQR]: 5–14 years), 10 years (IQR: 5–17) for Sp, and 1 year (IQR: 0–5) for Hi. 
Overall, average annual incidences for Nm, Sp, and Hi, respectively, were 7.5, 2.5, and 0.3 
per 100,000 (Table 3). The highest incidence of laboratory-confirmed meningitis was among 
children aged <1 year (20.4), with the lowest incidence observed among persons aged ≥30 
years (4.8) (Fig 3). The epidemiology of laboratory-confirmed meningitis varied widely by 
country and by year (Supplemental Figure).
Meningococcal meningitis
Though one-quarter (23%) of meningococcal meningitis cases occurred among children 
aged <5 years, the highest incidence was among adolescents aged 10–14 years (14.9) (Table 
4). Average annual Nm incidence varied by country: 14.7 in Niger, 12.5 in Togo, 2.7 in 
Chad, 1.5 in Burkina Faso, and 0.4 in Mali (Table 3).
Of the 2,433 reported meningococcal meningitis cases, 1,295 (53%) were NmC, 719 (30%) 
NmW, 315 (13%) NmX, 6 (0.2%) NmY, and 93 (4%) NmInd (Table 2). Five confirmed 
cases of NmA were reported, all in Burkina Faso during the 2014–2015 meningitis season, 
as previously described [17]; one of these cases was the first documented MACV vaccine 
failure. CFR did not significantly vary by serogroup: 6% for NmC, 6% for NmW, and 4% 
for NmX (P=0.2).
Seven notable meningococcal meningitis outbreaks occurred during this time period [18]: 
NmC in Niger in 2015–2017 (>9,000 suspected cases in 3 outbreaks) [19], NmC in Mali in 
2016 (39 suspected cases) [20], and NmW in Togo in 2016–2017 (>1,800 suspected cases in 
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3 outbreaks) [21]. NmW also predominated in Burkina Faso, and Chad detected mainly 
NmX. NmC and NmW accounted for the highest average annual incidences among 
meningococcal serogroups, 3.1 and 2.9 cases per 100,000, respectively (Table 3). NmX 
increased from 0.6% of Nm cases in 2015 to become the predominant meningococcal 
serogroup in 2017 (27% of Nm cases). Despite this increase and the wide distribution of 
NmX cases, NmX was not associated with any outbreaks during this time period. Only 6 
serogroup Y cases were reported in MenAfriNet districts: 4 in Burkina Faso in 2015 and 2 in 
Mali in 2017.
Pneumococcal meningitis
From 2015–2017, 1,758 meningitis cases were laboratory-confirmed as Sp, with a CFR of 
17% (Table 2). Incidence was highest among children aged <1 year (8.3 cases per 100,000), 
and was 1.7–3.7 in older age groups (Table 4). Sp was the predominant bacterial meningitis 
pathogen in Burkina Faso, Chad, and Mali (Table 3), causing 64% of laboratory-confirmed 
meningitis in those 3 countries. Overall, the incidence of pneumococcal meningitis in 
MenAfriNet districts declined from 4.1 per 100,000 in 2015 to 2.1 in 2017 (Fig 2), though 
incidence remained somewhat steady in children aged <5 years (3.7 in 2015, 2.4 in 2016, 3.9 
in 2017).
H. influenzae meningitis
A total of 180 Hi cases were reported in MenAfriNet districts (average annual incidence: 0.3 
cases per 100,000) (Tables 2 & 3). Incidence was highest in Chad (1.1) and lowest in Togo 
(0.1). Though there was a low reported incidence of Hi, it increased from 0.1 in 2015 to 0.5 
in 2017 (Fig 2). The highest incidence was among infants aged <1 year (3.2). Two-thirds 
(67%) of Hi cases were reported to be Hib: 71% occurred among children aged <5 years, 
and 11% were fatal; the remaining Hi cases were reported as non-b.
Discussion
This epidemiologic analysis showed that NmA incidence remains very low following 
MACV introduction, demonstrating continued positive vaccine impact in the eight years 
since introduction [17]. Despite the dramatic reduction in NmA disease following MACV 
introduction, bacterial meningitis epidemiology in this region continues to evolve and can 
vary widely by country and over time in the same country. Meningococcal meningitis due to 
non-A serogroups remains an endemic and epidemic threat. The overall epidemiology of 
meningococcal meningitis in MenAfriNet districts was driven primarily by several large 
outbreaks that occurred in this region during 2015–2017 [18]: NmC in Niger and Nigeria in 
2015–2017 following the emergence of a new strain (ST-10217) [20, 22–24], and NmW in 
Togo in 2016–2017 [21]. Reactive vaccination to these outbreaks may also have influenced 
local bacterial meningitis epidemiology in following years. Several countries reported 
increases in NmX, which became the predominant serogroup in 2017, though no NmX 
outbreaks were observed. The increased reporting of NmX may be partially attributed to a 
shift in case confirmation over time from latex agglutination to rt-PCR, as the commercially-
available latex agglutination test (Pastorex™) does not detect NmX whereas rt-PCR can 
confirm NmX cases. Regardless, this increase in reported NmX is concerning as there is no 
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currently licensed vaccine against NmX. An effective and affordable multivalent 
meningococcal conjugate vaccine targeting serogroups A, C, W, X, and Y could help further 
control meningococcal disease and epidemics in the region [25].
It is difficult to directly compare these presented incidences with incidences reported in this 
region prior to MACV introduction, due to differences such as laboratory methods used, 
sentinel-site vs. population-based surveillance, aggregate vs. case-based surveillance, annual 
incidence vs. incidence during outbreaks or peak weeks/months, and crude vs. adjusted 
incidences. However, some comparisons are possible and illustrative. For example, nearly all 
of these 2015–2017 incidences are lower than reported pre-MACV incidences in 
MenAfriNet countries. The incidence of suspected meningitis in Burkina Faso was 61 cases 
per 100,000 in 1997–2010 [2], compared to 14.7 in 2015–2017, and similarly 73 in Niamey, 
Niger in 2006 [26] vs. 52.5 in Niger in 2015–2017. Pre-MACV NmA incidence was 30.5 in 
Niamey in 1997 [27], 110 in western Burkina Faso in 2006 [28], 0.3 in Niamey in 2006 [26], 
and 70 in Tone, Togo in 2007 [28], compared to 0.01 in Burkina Faso and 0 in the other 
MenAfriNet countries in 2015–2017. In this analysis, the highest NmX incidence was in 
Togo in 2017 (7.7), though this was lower than previously published NmX incidences in 
Niamey in 1997 (15.1) [27] and 2006 (27.5) [26], and in Kozah, Togo in 2007 (33) [28]. 
However, pneumococcal meningitis incidence in Burkina Faso in 2015–2017 (32) was twice 
that reported in 3 districts in 2002–2005 (14) [29], and in Chad, suspected meningitis 
incidence in 2017 (20.5) was in between that reported in districts vaccinated (2.48) and 
unvaccinated (43.8) with MACV in 2012 [30].
The experience of the five key high-risk MenAfriNet countries in conducting high-quality 
meningitis surveillance demonstrates that long-term investment in case-based surveillance is 
a valuable platform both for monitoring evolving meningitis epidemiology and for 
evaluating the effectiveness of bacterial meningitis vaccines, especially MACV integration 
into routine immunization programs, pneumococcal conjugate vaccines, Hib conjugate 
vaccines, and a potential future multivalent meningococcal conjugate vaccine [25]. This 
network collects high-quality, case-based meningitis data in a region where the collection of 
high-quality surveillance data is a challenge, but is extremely important due to the high 
disease burden. These case-based data are a critical supplement to the conventional 
aggregate surveillance reporting via the Integrated Disease Surveillance and Response 
framework [8], as well as to enhanced meningitis surveillance being conducted elsewhere in 
the meningitis belt [31]. Therefore, maintenance of case-based surveillance in key high-
performing meningitis belt countries beyond the completion of the MenAfriNet project will 
help ensure continued availability of high-quality data to inform vaccine policy [32].
Only five cases of NmA were reported in MenAfriNet districts [17], providing further 
evidence of the ongoing effectiveness of MACV. These results support other analyses 
demonstrating the continued remarkable impact of MACV on both NmA carriage and 
disease throughout the meningitis belt [4, 5]. These findings, along with the high community 
acceptance [33], low cost of the vaccine, and long duration of protective immunity [34] 
(though shorter in children aged <5 years [35]) provide compelling evidence for continued 
MACV rollout in high-risk country areas inside or bordering the meningitis belt, via mass 
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campaigns, catch-up campaigns, and introduction into the routine immunization system for 
children aged 9–18 months [3, 36].
This analysis indicates that regional meningitis epidemiology continues to change following 
MACV introduction. S. pneumoniae was the predominant bacterial meningitis pathogen in 
Burkina Faso, Chad, and Mali during this time period, causing 64% of laboratory-confirmed 
meningitis in those 3 countries. In the meningitis belt, pneumococcal meningitis has a 
distinct seasonality similar to that of meningococcal meningitis, high CFR, and 
predominance of serotype 1 disease in persons aged >5 years [7, 29, 37–40]. In Burkina 
Faso, where pneumococcal serotype data have been analyzed, the introduction of 13-valent 
PCV in 2013 has resulted in a substantial (62%) reduction in meningitis due to PCV13-
serotypes, both among children aged <1 targeted for vaccination (77% reduction) and among 
older age groups benefitting from herd protection (~60% reduction) [7, 16, 39]. However, 
these declines were more pronounced among other PCV13 serotypes than for serotype 1, 
which continues to cause outbreaks in the region [40], indicating a potential need to 
reevaluate pneumococcal meningitis prevention and response strategies in the belt.
Despite the high-quality surveillance conducted in the five MenAfriNet countries, challenges 
to case-based meningitis surveillance in these countries remain. A perennial challenge is 
specimen transport. However, creative approaches to tracking specimens using barcodes and 
a cloud-based system in Burkina Faso may provide insights on how to improve this process 
and may be scaled up to other countries [41]. Ensuring that all suspected meningitis cases 
are reported, nearly all suspected meningitis cases have a CSF specimen collected, and every 
CSF specimen is received and tested at a national reference laboratory via culture or rt-PCR 
is key to high-quality case-based surveillance. While the MenAfriNet countries have worked 
towards increasing laboratory confirmation to support surveillance over time, 20% of CSF 
specimens still did not undergo laboratory confirmation at the national level, indicating 
remaining room for improvement [10]. Additionally, this case-based surveillance network 
only focuses on the clinical presentation of meningitis, and does not capture cases with non-
meningitis presentations such as meningococcemia [42], therefore presented incidences are 
minimal estimates of the full burden of invasive disease due to these pathogens. Despite 
these challenges, our reported incidence rates adjust for changes in culture and real-time 
PCR testing capacity over time and likely reflect true trends in pathogen-specific incidences 
for meningitis.
An immense effort has been invested in MACV vaccination campaigns in MenAfriNet 
countries and elsewhere in the belt, resulting in major successes in mobilizing international 
and local communities and encouraging high vaccine uptake, and in an extraordinary and 
unprecedented reduction in meningitis burden and NmA transmission. However, the data 
emphasize the importance of non-A serogroups and pneumococcal meningitis, and suggest 
that intensive meningitis surveillance with high levels of laboratory confirmation in a 
number of countries is needed to provide a representative picture of the dynamic regional 
epidemiology. Continued thoughtful and successful integration of MACV and PCV into 
childhood routine immunization programs, along with long-term investments in surveillance 
and a future multivalent meningococcal conjugate vaccine, could help to ensure that a goal 
of defeating meningitis by 2030 is met [32, 43].
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Fig 1. Epidemic curve of suspected meningitis cases reported per month to case-based meningitis 
surveillance in MenAfriNet districts, by country, 2015–2017.
Note: As Mali began data collection in 2015 and 2016 was the first complete year of 
surveillance, only 2016–2017 data are included. Similarly, only 2017 data from Chad are 
included.
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Fig 2. Adjusted annual incidence of bacterial meningitis by pathogen, MenAfriNet, 2015–2017.
A) 3 main bacterial meningitis pathogens: N. meningitidis (Nm), S. pneumoniae (Sp), and 
H. influenzae (Hi). B) Meningococcal serogroups: serogroup X (NmX), serogroup C 
(NmC), serogroup W (NmW), and serogroup A (NmA). Note: As Mali began data collection 
in 2015 and 2016 was the first complete year of surveillance, only 2016–2017 data are 
included. Similarly, only 2017 data from Chad are included.
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Fig 3. Average adjusted annual incidence of laboratory-confirmed meningitis by pathogen and 
age group, MenAfriNet, 2015–2017.
Abbreviations: Hi, H. influenzae; NmA, N. meningitidis serogroup A; NmC, N. meningitidis 
serogroup C; NmInd, N. meningitidis with indeterminate serogroup; NmW, N. meningitidis 
serogroup W; NmX, N. meningitidis serogroup X; NmY, N. meningitidis serogroup Y; Sp, 
S. pneumoniae.
Soeters et al. Page 14
J Infect Dis. Author manuscript; available in PMC 2020 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Soeters et al. Page 15
Ta
bl
e 
1.
Su
sp
ec
te
d 
an
d 
pr
ob
ab
le
 m
en
in
gi
tis
 c
as
es
 fr
om
 c
as
e-
ba
se
d 
m
en
in
gi
tis
 su
rv
ei
lla
nc
e,
 M
en
A
fri
N
et
, 2
01
5–
20
17
Bu
rk
in
a 
Fa
so
C
ha
da
M
al
ia
N
ig
er
To
go
To
ta
l
N
 (%
)
Su
sp
ec
te
d 
m
en
in
gi
tis
 c
as
es
8,
36
2
16
6
49
5
8,
41
3
82
6
18
,2
62
 
A
ge
 g
ro
up
b
 
 
<
1 
ye
ar
s
1,
42
7 
(17
)
46
 (3
1)
14
2 
(29
)
63
3 
(8)
11
6 
(14
)
2,
36
4 
(13
)
 
 
1–
4 
ye
ar
s
2,
78
3 
(33
)
41
 (2
8)
16
4 
(34
)
1,
60
6 
(20
)
10
4 
(13
)
4,
69
8 
(26
)
 
 
5–
9 
ye
ar
s
1,
53
9 
(18
)
23
 (1
6)
64
 (1
3)
1,
61
9 
(20
)
13
5 
(16
)
3,
38
0 
(19
)
 
 
10
–1
4 
ye
ar
s
1,
05
9 
(13
)
11
 (7
)
52
 (1
1)
1,
56
1 
(19
)
13
2 
(16
)
2,
81
5 
(16
)
 
 
15
–2
9 
ye
ar
s
88
3 
(11
)
12
 (8
)
39
 (8
)
1,
91
0 
(24
)
15
2 
(18
)
2,
99
6 
(17
)
 
 
≥3
0 
ye
ar
s
65
2 
(8)
15
 (1
0)
26
 (5
)
78
5 
(10
)
18
4 
(22
)
1,
66
2 
(9)
 
Se
x
c
 
 
Fe
m
al
e
3,
75
3 
(45
)
69
 (4
3)
21
5 
(43
)
3,
73
1 
(45
)
39
9 
(48
)
8,
16
7 
(45
)
 
 
M
al
e
4,
60
5 
(55
)
91
 (5
7)
28
0 
(57
)
4,
62
5 
(55
)
42
4 
(52
)
10
,0
25
 (5
5)
 
R
ep
or
te
d 
de
at
hs
d
77
2 
(9)
N
R
23
 (5
)
26
9 
(8)
31
 (4
)
1,
09
5 
(8)
Pr
ob
ab
le
 b
ac
te
ria
l m
en
in
gi
tis
 c
as
es
e
3,
59
8 
(44
)
71
 (4
3)
20
2 
(41
)
1,
94
5 
(27
)
37
4 
(47
)
6,
19
0 
(37
)
Po
pu
la
tio
n 
un
de
r s
ur
ve
ill
an
ce
 (2
01
7)
19
,6
32
,1
47
81
1,
41
4
4,
02
7,
82
9
7,
34
7,
84
0
96
3,
41
1
32
,7
82
,6
41
A
bb
re
v
ia
tio
ns
: N
R,
 n
ot
 re
po
rte
d.
a A
s M
al
i b
eg
an
 d
at
a 
co
lle
ct
io
n 
in
 2
01
5 
an
d 
20
16
 w
as
 th
e 
fir
st 
co
m
pl
et
e 
ye
ar
 o
f s
ur
ve
ill
an
ce
, o
nl
y 
20
16
–2
01
7 
da
ta
 ar
e i
nc
lu
de
d.
 S
im
ila
rly
,
 
o
n
ly
 2
01
7 
da
ta
 fr
om
 C
ha
d 
ar
e 
in
cl
ud
ed
.
b 3
47
 c
as
es
 a
re
 m
iss
in
g 
ag
e:
 1
9 
in
 B
ur
ki
na
 F
as
o
, 
18
 in
 C
ha
d,
 8
 in
 M
al
i, 
29
9 
in
 N
ig
er
,
 
an
d 
3 
in
 T
o
go
.
c 7
0 
ca
se
s a
re
 m
iss
in
g 
se
x
: 
4 
in
 B
ur
ki
na
 F
as
o
, 
6 
in
 C
ha
d,
 5
7 
in
 N
ig
er
,
 
an
d 
3 
in
 T
o
go
.
d P
er
ce
nt
ag
e 
ca
lc
ul
at
ed
 u
sin
g 
th
e 
nu
m
be
r o
f c
as
es
 w
ith
 a
 re
po
rte
d 
ou
tc
om
e 
(n=
12
,92
0, 
71
%)
 as
 th
e d
en
om
ina
tor
.
e P
er
ce
nt
ag
e 
ca
lc
ul
at
ed
 u
sin
g 
th
e 
nu
m
be
r o
f s
us
pe
ct
ed
 c
as
es
 w
ith
 a
 C
SF
 sp
ec
im
en
 (n
=1
6,8
85
, 9
2%
) a
s t
he
 de
no
mi
na
tor
.
J Infect Dis. Author manuscript; available in PMC 2020 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Soeters et al. Page 16
Ta
bl
e 
2.
La
bo
ra
to
ry
-c
on
fir
m
ed
 m
en
in
gi
tis
 c
as
es
 fr
om
 c
as
e-
ba
se
d 
m
en
in
gi
tis
 su
rv
ei
lla
nc
e,
 M
en
A
fri
N
et
, 2
01
5–
20
17
Bu
rk
in
a 
Fa
so
C
ha
da
M
al
ia
N
ig
er
To
go
To
ta
l
N
 (%
)
La
bo
ra
to
ry
-c
on
fir
m
ed
 m
en
in
gi
tis
 c
as
es
b
2,
22
4 
(27
)
64
 (3
9)
11
8 
(24
)
1,
70
1 
(24
)
26
4 
(33
)
4,
37
1 
(26
)
 
N
. m
en
in
gi
tid
is
67
1 
(30
)
22
 (3
4)
32
 (2
7)
1,
49
4 
(88
)
21
4 
(81
)
2,
43
3 
(56
)
 
 
Se
ro
gr
ou
p
 
 
 
A
5 
(1)
0
0
0
0
5 
(0.
2)
 
 
 
C
40
 (6
)
0
19
 (5
9)
1,
23
6 
(83
)
0
1,
29
5 
(53
)
 
 
 
W
47
8 
(71
)
2 
(9)
2 
(6)
10
9 
(7)
12
8 
(60
)
71
9 
(30
)
 
 
 
X
91
 (1
4)
20
 (9
1)
8 
(25
)
12
7 
(9)
69
 (3
2)
31
5 
(13
)
 
 
 
Y
4 
(1)
0
2 
(6)
0
0
6 
(0.
2)
 
 
 
N
m
In
dc
53
 (8
)
0
1 
(3)
22
 (1
)
17
 (8
)
93
 (4
)
 
 
R
ep
or
te
d 
de
at
hs
d
47
 (7
)
N
R
1 
(3)
59
 (6
)
6 
(3)
11
3 
(6)
 
S.
 p
ne
um
on
iae
1,
44
2 
(65
)
33
 (5
2)
58
 (4
9)
17
7 
(10
)
48
 (1
8)
1,
75
8 
(40
)
 
 
R
ep
or
te
d 
de
at
hs
d
24
5 
(17
)
N
R
6 
(10
)
14
 (1
6)
7 
(22
)
27
2 
(17
)
 
H
. i
nf
lu
en
za
e
11
1 
(5)
9 
(14
)
28
 (2
4)
30
 (2
)
2 
(1)
18
0 
(4)
 
 
Se
ro
ty
pe
 
 
 
Se
ro
ty
pe
 b
82
 (7
4)
5 
(56
)
18
 (6
4)
13
 (4
3)
2 
(10
0)
12
0 
(67
)
 
 
 
N
on
-b
 se
ro
ty
pe
s
29
 (2
6)
4 
(44
)
10
 (3
6)
17
 (5
7)
0
60
 (3
3)
 
 
R
ep
or
te
d 
de
at
hs
d
12
 (1
1)
N
R
1 
(4)
1 
(7)
0
14
 (9
)
A
bb
re
v
ia
tio
ns
: N
m
In
d,
 N
ei
ss
er
ia
 m
en
in
gi
tid
is 
w
ith
 in
de
te
rm
in
at
e 
se
ro
gr
ou
p;
 N
R,
 n
ot
 re
po
rte
d.
N
ot
e:
 C
as
e 
co
un
ts 
str
at
ifi
ed
 b
y 
co
un
try
,
 
pa
th
og
en
, a
ge
 g
ro
up
, a
nd
 y
ea
r a
re
 p
re
se
nt
ed
 in
 S
up
pl
em
en
ta
l T
ab
le
 2
.
a A
s M
al
i b
eg
an
 d
at
a 
co
lle
ct
io
n 
in
 2
01
5 
an
d 
20
16
 w
as
 th
e 
fir
st 
co
m
pl
et
e 
ye
ar
 o
f s
ur
ve
ill
an
ce
, o
nl
y 
20
16
–2
01
7 
da
ta
 ar
e i
nc
lu
de
d.
 S
im
ila
rly
,
 
o
n
ly
 2
01
7 
da
ta
 fr
om
 C
ha
d 
ar
e 
in
cl
ud
ed
.
b C
on
fir
m
ed
 v
ia
 la
te
x
 a
gg
lu
tin
at
io
n,
 c
ul
tu
re
, o
r r
ea
l-t
im
e 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
as
 N
. m
en
in
gi
tid
is,
 
S.
 p
ne
um
on
iae
,
 
o
r 
H
. i
nf
lu
en
za
e. 
Pe
rc
en
ta
ge
 c
al
cu
la
te
d 
us
in
g 
th
e 
nu
m
be
r o
f s
us
pe
ct
ed
 c
as
es
 w
ith
 a
 
CS
F 
sp
ec
im
en
 (n
=1
6,8
85
, 9
2%
) a
s t
he
 de
no
mi
na
tor
.
c O
f t
he
 9
3 
N
m
In
d 
ca
se
s, 
34
 (3
7%
) w
ere
 de
ter
mi
ne
d t
o b
e N
mI
nd
 vi
a r
ea
l-t
im
e p
oly
me
ras
e c
ha
in 
rea
cti
on
, 5
 (5
%)
 w
ere
 de
ter
mi
ne
d t
o b
e N
mI
nd
 vi
a c
ult
ure
, a
nd
 54
 (5
8%
) w
ere
 de
ter
mi
ne
d t
o b
e N
mI
nd
 as
 
th
ey
 o
nl
y 
ha
d 
la
te
x
 a
gg
lu
tin
at
io
n 
re
su
lts
 av
ai
la
bl
e,
 w
hi
ch
 w
er
e 
N
m
W
/Y
,
 
pr
ec
lu
di
ng
 id
en
tif
ic
at
io
n 
of
 a
 sp
ec
ifi
c 
se
ro
gr
ou
p.
d P
er
ce
nt
ag
e 
ca
lc
ul
at
ed
 u
sin
g 
th
e 
nu
m
be
r o
f c
as
es
 w
ith
 a
 re
po
rte
d 
ou
tc
om
e 
as
 th
e 
de
no
m
in
at
or
.
J Infect Dis. Author manuscript; available in PMC 2020 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Soeters et al. Page 17
Ta
bl
e 
3.
Av
er
ag
e 
an
nu
al
 in
ci
de
nc
e 
(ca
ses
 pe
r 1
00
,00
0 p
ers
on
s) 
of 
su
sp
ec
ted
, p
rob
ab
le 
an
d l
ab
ora
tor
y-c
on
fir
m
ed
 m
en
in
gi
tis
, M
en
A
fri
N
et
, 2
01
5–
20
17
Bu
rk
in
a 
Fa
so
C
ha
da
M
al
ia
N
ig
er
To
go
Av
er
a
ge
 a
nn
ua
l i
nc
id
en
ce
b
Su
sp
ec
te
d 
m
en
in
gi
tis
 c
as
es
c
14
.7
20
.5
6.
3
52
.5
47
.2
31
.3
Pr
ob
ab
le
 m
en
in
gi
tis
 c
as
es
c
6.
3
8.
8
2.
6
11
.9
22
.1
11
.2
La
bo
ra
to
ry
-c
on
fir
m
ed
 m
en
in
gi
tis
 c
as
es
d
5.
0
7.
9
1.
6
16
.7
15
.9
10
.3
 
N
. m
en
in
gi
tid
is
1.
5
2.
7
0.
4
14
.7
12
.5
7.
5
 
 
Se
ro
gr
ou
p
 
 
 
A
0.
01
0
0
0
0
0.
00
3e
 
 
 
C
0.
1
0
0.
3
12
.1
f
0
3.
1
 
 
 
W
1.
1
0.
2
0.
03
1.
4
8.
9
2.
9
 
 
 
X
0.
2
2.
5
0.
1
0.
9
2.
8
1.
2
 
 
 
Y
0.
01
0
0.
03
0
0
0.
01
 
 
 
N
m
In
d
0.
1
0
0.
01
0.
3
0.
8
0.
3
 
S.
 p
ne
um
on
iae
3.
2
4.
1
0.
8
1.
8
3.
2
2.
5
 
H
. i
nf
lu
en
za
e
0.
2
1.
1
0.
4
0.
2
0.
1
0.
3
A
bb
re
v
ia
tio
n:
 N
m
In
d,
 N
ei
ss
er
ia
 m
en
in
gi
tid
is 
w
ith
 in
de
te
rm
in
at
e 
se
ro
gr
ou
p.
N
ot
e:
 C
al
cu
la
te
d 
in
ci
de
nc
es
 a
re
 o
nl
y 
fo
r d
ist
ric
ts 
pa
rti
ci
pa
tin
g 
in
 M
en
A
fri
N
et
 in
 e
ac
h 
co
un
try
.
 
In
ci
de
nc
es
 b
y 
co
un
try
,
 
ye
ar
,
 
an
d 
pa
th
og
en
 a
re
 sh
ow
n
 in
 th
e 
Su
pp
le
m
en
ta
l F
ig
ur
e.
a A
s M
al
i b
eg
an
 d
at
a 
co
lle
ct
io
n 
in
 2
01
5 
an
d 
20
16
 w
as
 th
e 
fir
st 
co
m
pl
et
e 
ye
ar
 o
f s
ur
ve
ill
an
ce
, o
nl
y 
20
16
–2
01
7 
da
ta
 ar
e i
nc
lu
de
d.
 S
im
ila
rly
,
 
o
n
ly
 2
01
7 
da
ta
 fr
om
 C
ha
d 
ar
e 
in
cl
ud
ed
.
b M
en
A
fri
N
et
-w
id
e 
av
er
ag
e 
an
nu
al
 in
ci
de
nc
es
 w
er
e 
ca
lc
ul
at
ed
 b
y 
av
er
ag
in
g 
th
e 
ad
jus
ted
 an
nu
al 
inc
ide
nc
es 
fro
m 
pa
rtic
ipa
tin
g d
ist
ric
ts 
in 
eac
h c
ou
ntr
y f
or 
eac
h y
ear
 of
 th
eir
 pa
rtic
ipa
tio
n i
n M
en
Af
riN
et.
c C
ru
de
 in
ci
de
nc
e.
d C
on
fir
m
ed
 v
ia
 la
te
x
 a
gg
lu
tin
at
io
n,
 c
ul
tu
re
, o
r r
ea
l-t
im
e 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
as
 N
. m
en
in
gi
tid
is,
 
S.
 p
ne
um
on
iae
,
 
o
r 
H
. i
nf
lu
en
za
e. 
In
ci
de
nc
e 
ad
jus
ted
 fo
r a
ge
 an
d t
he
 pr
op
ort
ion
 of
 ca
ses
 w
ith
 
ce
re
br
os
pi
na
l f
lu
id
 te
ste
d 
at
 a
 n
at
io
na
l r
ef
er
en
ce
 la
bo
ra
to
ry
.
 
A
n 
in
ci
de
nc
e 
of
 0
 in
di
ca
te
s n
o 
co
nf
irm
ed
 c
as
es
 w
ith
 th
at
 sp
ec
ifi
c 
pa
th
og
en
 in
 th
at
 c
ou
nt
ry
.
 
It 
is 
po
ss
ib
le
 fo
r t
he
 c
ru
de
 in
ci
de
nc
e 
of
 p
ro
ba
bl
e 
m
en
in
gi
tis
 to
 b
e 
lo
w
er
 th
an
 th
e 
ad
jus
ted
 in
cid
en
ce 
of 
lab
ora
tor
y-c
on
fir
m
ed
 m
en
in
gi
tis
, w
hi
ch
 w
as
 a
dju
ste
d t
o a
cco
un
t fo
r c
ase
s w
ith
 no
 co
nfi
rm
at
or
y 
la
bo
ra
to
ry
 re
su
lts
 av
ai
la
bl
e.
e O
nl
y 
5 
N
m
A
 ca
se
s r
ep
or
te
d 
in
 B
ur
ki
na
 F
as
o
 in
 th
e 
20
15
 m
en
in
gi
tis
 se
as
on
.
f A
v
er
ag
e 
an
nu
al
 N
m
C 
in
ci
de
nc
e 
in
 N
ig
er
 is
 d
riv
en
 b
y 
th
e 
20
15
 N
m
C 
ep
id
em
ic
: 2
01
5 
N
m
C 
in
ci
de
nc
e:
 2
1.
5,
 as
 co
m
pa
re
d 
to
 4
.1
 in
 2
01
6 
an
d 
10
.8
 in
 2
01
7.
J Infect Dis. Author manuscript; available in PMC 2020 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Soeters et al. Page 18
Ta
bl
e 
4.
Av
er
ag
e 
an
nu
al
 in
ci
de
nc
e 
(ca
ses
 pe
r 1
00
,00
0 p
ers
on
s) 
of 
lab
ora
tor
y-c
on
fir
m
ed
 m
en
in
gi
tis
 b
y 
pa
th
og
en
 a
nd
 a
ge
 g
ro
up
, M
en
A
fri
N
et
, 2
01
5–
20
17
Bu
rk
in
a 
Fa
so
C
ha
da
M
al
ia
N
ig
er
To
go
Av
er
a
ge
 a
nn
ua
l i
nc
id
en
ce
b
N
. m
en
in
gi
tid
is
 
<
1 
ye
ar
2.
3
3.
4
1.
4
10
.8
20
.1
8.
8
 
1–
4 
ye
ar
s
2.
6
3.
9
0.
7
14
.2
10
.8
7.
3
 
5–
9 
ye
ar
s
2.
9
3.
6
0.
2
21
.4
21
.8
11
.8
 
10
–1
4 
ye
ar
s
2.
4
3.
6
1.
2
31
.2
24
.0
14
.9
 
15
–2
9 
ye
ar
s
0.
6
1.
9
0.
3
13
.6
7.
5
5.
6
 
≥3
0 
ye
ar
s
0.
3
0
0.
1
1.
5
8.
4
2.
6
S.
 p
ne
um
on
iae
 
<
1 
ye
ar
8.
4
27
.4
4.
4
8.
5
4.
3
8.
3
 
1–
4 
ye
ar
s
2.
7
6.
3
1.
3
1.
5
0.
9
2.
0
 
5–
9 
ye
ar
s
4.
8
2.
9
0.
6
0.
7
2.
1
2.
2
 
10
–1
4 
ye
ar
s
5.
6
2.
7
0.
8
2.
5
5.
3
3.
7
 
15
–2
9 
ye
ar
s
2.
3
0.
5
0.
7
1.
6
2.
3
1.
7
 
≥3
0 
ye
ar
s
1.
5
2.
5
0.
1
1.
2
5.
1
2.
2
H
. i
nf
lu
en
za
e
 
<
1 
ye
ar
2.
9
13
.7
5.
6
1.
8
0
3.
2
 
1–
4 
ye
ar
s
0.
5
0.
8
0.
6
0.
2
0.
9
0.
6
 
≥5
 y
ea
rs
0.
1
0.
5
0.
1
0.
2
0
0.
1
N
ot
e:
 C
as
es
 w
er
e 
co
nf
irm
ed
 v
ia
 la
te
x
 a
gg
lu
tin
at
io
n,
 c
ul
tu
re
, o
r r
ea
l-t
im
e 
po
ly
m
er
as
e 
ch
ai
n 
re
ac
tio
n 
as
 N
. m
en
in
gi
tid
is,
 
S.
 p
ne
um
on
iae
,
 
o
r 
H
. i
nf
lu
en
za
e. 
Ca
lc
ul
at
ed
 in
ci
de
nc
es
 a
re
 o
nl
y 
fo
r d
ist
ric
ts 
pa
rti
ci
pa
tin
g 
in
 M
en
A
fri
N
et
 in
 e
ac
h 
co
un
try
.
 
In
ci
de
nc
e 
ad
jus
ted
 fo
r a
ge
 an
d t
he
 pr
op
ort
ion
 of
 ca
ses
 w
ith
 ce
reb
ros
pin
al 
flu
id 
tes
ted
 at
 a 
na
tio
na
l re
fer
en
ce 
lab
ora
tor
y. 
A
n 
in
ci
de
nc
e 
of
 0
 in
di
ca
te
s n
o 
co
n
fir
m
ed
 c
as
es
 w
ith
 th
at
 sp
ec
ifi
c 
pa
th
og
en
 in
 M
en
A
fri
N
et
 d
ist
ric
ts 
in
 th
at
 c
ou
nt
ry
.
a A
s M
al
i b
eg
an
 d
at
a 
co
lle
ct
io
n 
in
 2
01
5 
an
d 
20
16
 w
as
 th
e 
fir
st 
co
m
pl
et
e 
ye
ar
 o
f s
ur
ve
ill
an
ce
, o
nl
y 
20
16
–2
01
7 
da
ta
 ar
e i
nc
lu
de
d.
 S
im
ila
rly
,
 
o
n
ly
 2
01
7 
da
ta
 fr
om
 C
ha
d 
ar
e 
in
cl
ud
ed
.
b M
en
A
fri
N
et
-w
id
e 
av
er
ag
e 
an
nu
al
 in
ci
de
nc
es
 w
er
e 
ca
lc
ul
at
ed
 b
y 
av
er
ag
in
g 
th
e 
ad
jus
ted
 an
nu
al 
inc
ide
nc
es 
fro
m 
pa
rtic
ipa
tin
g d
ist
ric
ts 
in 
eac
h c
ou
ntr
y f
or 
eac
h y
ear
 of
 th
eir
 pa
rtic
ipa
tio
n i
n M
en
Af
riN
et.
J Infect Dis. Author manuscript; available in PMC 2020 October 31.
